



## DATA SHEET

**For research use only. Not for use in humans.**

<b>Reagent:</b>	Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Protein (2909)
<b>Catalog Number:</b>	ARP-12141
<b>Lot Number:</b>	160080
<b>Release Category:</b>	E
<b>Provided:</b>	Each vial of ARP-12141 contains approximately 100 micrograms of purified antibody in phosphate-buffered saline (PBS) at a concentration of 4.16 milligrams per milliliter.
<b>Description:</b>	ARP-12141 is a monoclonal antibody to HIV-1 gp120 protein, specific for the V2V3 quaternary neutralizing epitope (QNE).
<b>Host or Host Site:</b>	Human, Epstein-Barr virus (EBV)-transformed cells fused to SHM-D33 heteromyeloma cells
<b>Special Characteristics:</b>	This antibody was derived by EBV transformation of cells and is directed against the V2V3 QNE. This antibody potentially neutralizes the SF162 virus and is not cross-reactive.
<b>Recommended Storage:</b>	Keep at 4°C only for short-term storage and -80°C for long-term storage. Avoid freeze-thaw cycles as reagent degradation may result.
<b>Contributor:</b>	Dr. Susan Zolla-Pazner
<b>Isotype:</b>	IgG1, lambda
<b>References:</b>	<p>Gorny, M. K., et al. "Identification of a New Quaternary Neutralizing Epitope of Human Immunodeficiency Virus Type I Virus Particles." <i>J. Virol.</i> 79 (2005): 5232-5237. PubMed: <a href="#">15795308</a>.</p> <p>Honnen, W. J., et al. "Type-Specific Epitopes Targeted by Monoclonal Antibodies with Exceptionally Potent Neutralizing Activities for Selected Strains of HIV-1 Map to a Common Region of the V2 Domain of gp120 and Differ only at a Single Position from the Clade B Consensus." <i>J. Virol.</i> 81 (2007): 1424-1432. PubMed: <a href="#">17121806</a>.</p> <p>Spurrier, B., et al. "Structural Analysis of Human and Macaque mAbs 2909 and 2.5B: Implications for the Configuration of the Quaternary Neutralizing Epitope of HIV-1 gp120." <i>Structure</i> 19 (2011): 691-699. PubMed: <a href="#">21565703</a>.</p> <p>Wu, X., et al. "Immunotypes of a Quaternary Site of HIV-1 Vulnerability and Their Recognition by Antibodies." <i>J. Virol.</i> 85 (2011): 4578-4585. PubMed: <a href="#">21325411</a>.</p>
<b>Citation:</b>	Acknowledgment for publications should read "The following reagent was obtained through the NIH HIV Reagent Program, Division of AIDS, NIAID, NIH: Monoclonal Anti-Human Immunodeficiency Virus Type 1 (HIV-1) gp120 Protein (2909), ARP-12141, contributed by Dr. Susan Zolla-Pazner." Also include the references cited in any publications.
<b>Biosafety Level: 1</b>	Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <i>Biosafety in Microbiological and Biomedical Laboratories</i> . 6th ed. Washington, DC: U.S. Government Printing Office, 2020; see <a href="http://www.cdc.gov/biosafety/publications/bmbl5/index.htm">www.cdc.gov/biosafety/publications/bmbl5/index.htm</a> .

**Disclaimers:**

You are authorized to use this product for research use only. It is not intended for use in humans.

Use of this product is subject to the terms and conditions of the NIH HIV Reagent Program Material Transfer Agreement (MTA). The MTA is available on our Web site at [www.hivreagentprogram.org](http://www.hivreagentprogram.org).

While the NIH HIV Reagent Program uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to the NIH HIV Reagent Program are not liable for damages arising from the misidentification or misrepresentation of products.

**Use Restrictions:**

**This material is distributed for internal research purposes only.** This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

**Note:**

**Corporate requests should be directed in writing to Dr. Susan Zolla-Pazner at the Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1090, New York, NY 10029.**

**The contributor has requested to be informed at least two weeks before submitting a document for publication or making a public oral presentation of research results obtained from the use of this material, in writing or by providing a copy of the publication document.**

**Recipient must not use or incorporate the reagent for commercial purposes.**

ATCC® is a trademark of the American Type Culture Collection.

